title: [Pathological diagnosis for individualized therapy of colorectal cancer].
abstract: Pathological diagnosis is essential today for the individualized therapy of colorectal cancer. In the routine analysis of colorectal carcinomas the molecular-pathological detection of a KRAS mutation predicts unresponsiveness to EGFR-targeted antibody therapies. Moreover, the detection of mismatch-repair deficiency or high-degree microsatellite instability indicates unresponsiveness to 5-FU monotherapy. Colorectal carcinomas with high-grade microsatellite instability and their associated morphologic subtypes, such as the medullary carcinoma, exhibit a low risk of distant metastasis and might be considered as carcinomas with low need for adjuvant chemotherapy.
authors: Pathologisches Institut der Ludwig-Maximilians-Universität München, Thalkirchner Strasse 36, Munich, Germany. thomas.kirchner@med.uni-muenchen.de
authors: T
authors: T
authors: Kirchner
authors: A
authors: A
authors: Jung
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068818:Cetuximab; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology*; D003131:Combined Modality Therapy; D053843:DNA Mismatch Repair / Q000235:genetics; D004252:DNA Mutational Analysis; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D005472:Fluorouracil / Q000009:adverse effects / Q000627:therapeutic use; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects / Q000627:therapeutic use; D053842:Microsatellite Instability; D009419:Nerve Tissue Proteins / Q000235:genetics; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000077544:Panitumumab; D010597:Pharmacogenetics; D017410:Practice Guidelines as Topic; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D016601:RNA-Binding Proteins / Q000235:genetics; D018631:ras Proteins / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; C491297:MSI1 protein, human; D009419:Nerve Tissue Proteins; D009944:Organoplatinum Compounds; D011518:Proto-Oncogene Proteins; D016601:RNA-Binding Proteins; D000077544:Panitumumab; C512478:EGFR protein, human; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002955:Leucovorin; D005472:Fluorouracil